$2.52
3.28%
Nasdaq, Sep 17, 04:15 pm EDT. Closed.
ISIN
US31189P1021
Symbol
FATE

Fate Therapeutics, Inc. Stock price

$2.52
-0.10 3.82% 1M
+1.39 123.01% 6M
+1.54 156.46% YTD
+1.57 165.26% 1Y
-0.03 1.18% 3Y
-69.08 96.48% 5Y
-0.48 16.00% 10Y
-4.10 61.93% 20Y
Nasdaq, Closing price Thu, Sep 17 2026
+0.08 3.28%
ISIN
US31189P1021
Symbol
FATE
Industry

Is Fate Therapeutics, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,134 stocks worldwide.

Key metrics

Basic
Market capitalization
$292.4m
Enterprise Value
$150.5m
Net debt
positive
Cash
$153.8m
Shares outstanding
116.7m
Valuation (TTM | estimate)
P/E
negative
P/S
45.0 | 49.0
EV/Sales
23.2 | 25.2
EV/FCF
negative
P/B
1.9
Financial Health
Equity Ratio
65.0%
Return on Equity
-65.8%
ROCE
-58.7%
ROIC
-
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
$6.5m | $6.0m
EBITDA
$-121.6m
EBIT
$-133.6m
Net Income
$-126.0m
Free Cash Flow
$-105.7m
Growth (TTM | estimate)
Revenue
-23.4% | -10.3%
EBITDA
31.0%
EBIT
30.6%
Net Income
26.5%
Free Cash Flow
11.0%
Margin
Gross
-
EBITDA
-1,873.4%
EBIT
-2,058.1%
Net
-1,941.1%
Free Cash Flow
-1,627.8%
More
EPS
$-1.1
FCF per Share
$-0.9
Short interest
8.6%
Employees
161
Rev per Employee
$40.0k

Fate Therapeutics, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

18 Analysts have issued a Fate Therapeutics, Inc. forecast:

11x Buy
61%
7x Hold
39%

Analyst Opinions

18 Analysts have issued a Fate Therapeutics, Inc. forecast:

Buy
61%
Hold
39%

Financial data from Fate Therapeutics, Inc.

Jun '26
+/-
%
6.49 6.49
23% 23%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 40 40
35% 35%
612%
- Research and Development Expense 100 100
20% 20%
1,546%
-122 -122
31% 31%
-1,874%
- Depreciation and Amortization 12 12
25% 25%
185%
EBIT (Operating Income) EBIT -134 -134
31% 31%
-2,058%
Net Profit -126 -126
27% 27%
-1,941%

In millions USD.

Don't miss a Thing! We will send you all news about Fate Therapeutics, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Fate Therapeutics, Inc. Stock News

Neutral
GlobeNewsWire
one day ago
SAN DIEGO, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disease, today announced that four abstracts from its off-the-shelf CAR T-cell programs have been selected f...
Neutral
GlobeNewsWire
8 days ago
SAN DIEGO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a transformative pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced clinical data from its off-the-shelf anti-CD19 CAR T-cell product candidate FT819,...
Neutral
GlobeNewsWire
about one month ago
First patient dosed in an outpatient setting, discharged the same day; multiple patients in the process of screening at several activated sites
More Fate Therapeutics, Inc. News

Company Profile

Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products include immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.

Head office United States
CEO Dr. Valamehr
Employees 161
Founded 2007
Website fatetherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today